The Synaptic Vesicle Protein 2A Interacts With Key Pathogenic Factors in Alzheimer’s Disease: Implications for Treatment [PDF]
Frontiers in Cell and Developmental Biology, 2021 Alzheimer’s disease (AD), a serious neurodegenerative disease, is pathologically characterized by synaptic loss and dysfunction. Synaptic vesicle protein 2A (SV2A) is an indispensable vesicular protein specifically expressed in synapses and can be used ...
Yanyan Kong +15 more
doaj +4 more sources
Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment [PDF]
Brain Sciences, 2021 Synaptic vesicle protein 2A (SV2A), the target of the antiepileptic drug levetiracetam (LEV), is expressed ubiquitously in all synaptic terminals. Its levels decrease in patients and animal models of epilepsy.
Itzel Jatziri Contreras-García +6 more
doaj +3 more sources
Identification of the antiepileptic racetam binding site in the vesicle synaptic protein 2A by molecular dynamics and docking simulations [PDF]
Frontiers in Cellular Neuroscience, 2015 Synaptic vesicle protein 2A (SV2A) is an integral membrane protein necessary for the proper function of the central nervous system (CNS) and is associated to the physiopathology of epilepsy.
José eCorrea-Basurto +8 more
doaj +2 more sources
Reduced synaptic vesicle protein 2A in extracellular vesicles and brains of Alzheimer’s disease: associations with Aβ, tau, synaptic proteins and APOE ε4 [PDF]
Translational NeurodegenerationBackground Alzheimer’s disease (AD) is characterized by accumulation of amyloid-β (Aβ) plaques, tau neurofibrillary Tangles and synaptic dysfunction.
Jana Nussbaumer +14 more
doaj +2 more sources
Recognition of antiepileptic brivaracetam by synaptic vesicle protein 2A [PDF]
Cell DiscoveryShujin Liu +6 more
doaj +2 more sources
Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery [PDF]
BiomedicinesMajor depressive disorder remains a leading cause of disability, and decades of monoamine-centered pharmacology have yielded delayed and often incomplete relief.
Masaru Tanaka
doaj +2 more sources
The Rise of Synaptic Density PET Imaging
Molecules, 2020 Many neurological disorders are related to synaptic loss or pathologies. Before the boom of positrons emission tomography (PET) imaging of synapses, synaptic quantification could only be achieved in vitro on brain samples after autopsy or surgical ...
Guillaume Becker +3 more
doaj +1 more source
First-in-Human PET Imaging of [18F]SDM-4MP3: A Cautionary Tale
Molecular Imaging, 2023 [18F]SynVesT-1 is a PET radiopharmaceutical that binds to the synaptic vesicle protein 2A (SV2A) and serves as a biomarker of synaptic density with widespread clinical research applications in psychiatry and neurodegeneration.
Kimberly L. Desmond +13 more
doaj +1 more source
Structural basis for botulinum neurotoxin E recognition of synaptic vesicle protein 2
Nature Communications, 2023 Botulinum neurotoxin E (BoNT/E) is one of the major causes of human botulism and paradoxically also a promising therapeutic agent. Here we determined the co-crystal structures of the receptor-binding domain of BoNT/E (HCE) in complex with its neuronal ...
Zheng Liu +14 more
doaj +1 more source
Levetiracetam as a Potent and Safe Antiepileptic Drug [PDF]
Minia Journal of Medical Research, 2020 A group of new antiepileptic drugs (AEDs) has been clinically established and used. Most of these drugs have new mechanisms of actions that differ from older drugs. Levetiracetam (LEV), a secondgeneration AEDs, is a pyrrolidine derivate compound.
Hatem Sarhan +3 more
doaj +1 more source